Clinical and molecular characterization of a novel MYCN related syndrome – A mirror phenotype and molecular of the Feingold syndrome

Targeted gene(s)/phenotype under study :

  • MYCN (OMIM# 164840); Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome spectrum

Abstract :

We identified a de novo variant in MYCN, in a foetus with a mirror phenotype of the Feingold syndrome. To date, only one patient (post-natal) has been described, with a similar mirror phenotype (PMID: 30573562). It suggests a gain-of-function mechanism, rather than a loss-of-function as described in the Feingold syndrome.

Therefore, we are collecting, already identified variants in MYCN , localized between amino-acids 50 and 70, in patients within the megalencephaly polymicrogyrya polydactyly hydrocephalus spectrum (MPPH), and negative for another molecular cause.

We have the possibility to perform functional assay on the identified MYCN variant with the collaborators from the initial publication, whom we are working with.

Coordinating clinicians/researchers: Dr. Frederic Tran-Mau-Them

Institution :

UF6254 Innovation en Diagnostic Genomique des Maladies Rares

CHU Dijon,

France

Contact : Frederic.tran-mau-them@u-bourgogne.fr   

Specific requirements beyond clinical data and genotype data sharing:

  • Re-analysis of DNA samples : Y if necessary (by the inclusion centre)
  • Resampling of patients : N
  • Linked to a translational/basic research project? Y (collaboration with a Japanese team on functional assay)